Dr. Bill Grady and colleagues review the status of chemopreventatives for progression of Barrett's to esophageal adenocarcinoma
Joel Rubenstein and colleagues report increased risk of Barrett's associated with a family history of esophageal or colorectal cancer, supporting previous research.
Cost-effectiveness modeling from UK indicates that endoscopic eradiction therapy for both low and high-grade dysplasia is cost-effective compared to surveillance.
Long term outcomes from SURF clinical trial of RFA for low grade dysplasia confirms strong benefit in risk of HGD or esophageal adenocarcinoma.
Ireland consortium estimates progression from Barrett's to esophageal adenocarcinoma or high grade dysplasia, finding risks similar to previous studies, but higher risk among confirmed low grade dysplasias.
In this publication, the American Society for Gastrointestinal Endoscopy updated their guidelines for screening/surveillance of BE. ASGE guideline on screening and surveillance of Barrett’sesophagusGastrointest Endosc. 2019 Sep;90(3):335-359.e2.